Table 2.
Enzyme-responsive srNPs in cancer therapy.
| Stimulus | Responsive Moiety | Nanoplatform | Cargos | Application | Tumor Model | Refs. |
|---|---|---|---|---|---|---|
| Cathepsin B | GFLG | DOX@MSN-GFLGR7RGDS/α-CD | DOX | Tumor targeted chemotherapy | HeLa | [106] |
| RH-(GFLG)3 | DOX | Tumor targeted chemotherapy | HeLa | [110] | ||
| FRRG | FRRG-DOX | DOX | Tumor targeted chemotherapy | HT-29 | [108] | |
| FRRG-MMAE | MMAE | Tumor targeted chemotherapy | 4T1 | [109] | ||
| MMP-2 | GPLGIAGQ | PEG2000-peptide-PTX | PTX | MMP-2-sensitive drug release | A549 | [115] |
| GPLGLAG | MPV-HOAD | OXA pheophorbide a |
MMP-2-sensitive PDT and cancer immunotherapy | CT26 | [116] | |
| MMP-9 | GFFLG PhAc-FFAG |
MMP-9 responsive peptides in conjunction with DOX | DOX | MMP-9-triggered drug release and chemotherapy | MDA-MB-231-luc-D3H2LN | [117] |
| MMP-13 | PLGLAR | MSNs-PLGLAR-BSA-LA@DOX | DOX | MMP-13-triggered drug release and chemotherapy | HepG2 | [118] |
| sPLA2 | 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine | liposome shells and TRAIL-loaded DNA NCs cores | TRAIL | Targeted Delivery of Cytokine | COLO 205 cells | [120] |
| ester bonds in proAEL | proAEL | AEL | Tumor specific drug release for cancer therapy | KATO III | [121] | |
| phosphate | UCNP-loaded phosphate micelles | UCNP | Bioimaging of prostate cancer cells | 22Rv1 | [122] | |
| DSPC/DSPG/DSPE | DSPC/DSPG/DSPE liposomes | PNA | tumor targeted drug release for cancer therapy | Hela | [123] | |
| Galactosidase | Saccharides | SMPS modified with lactose or starch derivatives | [Ru(bipy)3]2+ dye | Glycosidase-responsive intracellular controlled release of drug | HeLa | [126] |
| Galactosidase | Carbohydrate unit | folate-DOX conjugate | DOX | Glycosidase-responsive chemotherapy | KG-1 and HL-60 | [127] |
| α-glucosidase | β-CD | β-CD-MNPs | prodigiosin | Anticancer drug delivery | MCF-7/GFPHepG2 | [128] |